Green Monke Expands Southeast Presence With South Carolina Launch
With This Launch, Green Monke's Portfolio of Premium Hemp Beverages are now Available to a Growing Number of Consumers Across 9 States
CHARLESTON, SOUTH CAROLINA - March 25, 2025 ( NEWMEDIAWIRE) - Green Monke USA ('Green Monke'), an award-winning hemp-D9 beverage brand, has entered into a distribution agreement with Southern Horizon Logistics in partnership with Southern Crown Partners, the premier beer distributor in South Carolina. Green Monke has now fulfilled the first purchase orders, delivering the brand's full portfolio of 8 SKUs - including its flagship, Green Monke Happy Soda line, and the Cookies by Green Monke collaboration.
'With Southern Crown, we're not just expanding access to premium hemp-derived beverages - we're leading the charge. Our Happy Soda line offers a refreshing, social, alcohol alternative, while Cookies by Green Monke is a bold tribute to THC enthusiasts, delivering cultivar-inspired flavors that set a new standard for THC beverages,' said Pat Gleeson, CEO of Green Monke. 'Partnering with Cookies - the most recognized cannabis brand worldwide -gives us unmatched cultural credibility. This collaboration bridges legacy connoisseurs and curious newcomers, ensuring Southern Crown stays ahead in curating the best THC beverage portfolio on the market.'
This launch builds upon Green Monke's successful introduction in Georgia last fall, further establishing its presence in the Southeast and comes at a pivotal time as South Carolina implements new regulations clarifying the legality of hemp-derived THC products. In a recent opinion, State Solicitor General Robert Cook confirmed that beverages compliant with the 2018 Farm Bill, including those adhering to delta-9 THC limits, are fully legal. This regulatory clarity has created a stable framework for businesses like Green Monke to confidently expand within the state, offering retailers and consumers new, popular, and innovative products.
Green Monke's Expanding National Footprint
Green Monke's rapid expansion continues as the brand reaches new markets, where it is available in over nine states, including Georgia, Florida, North Carolina, Minnesota, Wisconsin and, now, South Carolina, among others. With this latest launch, Green Monke's innovative hemp-derived THC beverages are now accessible to a combined population of more than 80 million consumers, reinforcing the brand's commitment to bring its high-quality and award-winning alcohol alternatives to an ever-growing audience.
This milestone underscores Green Monke's mission to lead the THC beverage category, offering an inclusive and enjoyable experience for both seasoned consumers and newcomers alike. As the brand extends its footprint across the country, its presence can now be felt in a diverse range of locations - from liquor stores and major retailers to bars, restaurants, and event venues like Enmarket Arena and The Pabst Theater Group properties.
By building strong distribution partnerships and securing placements in these high-traffic environments, Green Monke ensures that its expanding portfolio - including the signature Happy Soda line and the exclusive Cookies by Green Monke collaboration - continues to set the standard for quality, taste, and cultural relevance in the hemp beverage market.
To learn more about Green Monke Happy Sodas and purchase products visit: www.greenmonkehemp.com/s/shop.
About Southern Horizon Logistics
Southern Horizon Logistics, in partnership with Southern Crown Partners, is one of the oldest Anheuser-Busch distributors in the country and one of the largest in the Southeast. Today, we strive to become a 'one stop shop' beverage wholesaler serving 61 counties throughout SC & GA. Their 725 team members work together to distribute everything from energy drinks, coconut water, cider, hard kombucha, boozy tea, cold-brew coffee, performance drinks, beer, wine, and spirits. More information is available at scpdist.com.
About Green Monke
Founded in 2022 by St. Peter's Spirits, Green Monke USA has swiftly emerged as a leader in the hemp-infused beverage industry, known for its award-winning taste, innovative offerings and high-quality products. Recognized both in North America and Europe, Green Monke offers a diverse product range, featuring hemp-based Delta-9 drinks offered to the mass markets, and a regulated cannabis-infused beverage line made available in regulated dispensaries. These products provide a casual buzz, making them a favored substitute for alcoholic drinks during social occasions.
As part of its strategy to evolve the happy hour experience, Green Monke entered into a strategic, global licensing partnership with Cookies, the most recognized cannabis brand, introducing a line of co-branded infused beverages now accessible at Cookies outlets worldwide. Green Monke is also working with the Oak View Group (OVG), a global sports and entertainment company, to offer its Happy Sodas at select OVG venues in the U.S. This partnership underscores Green Monke's commitment to bring its high-quality and award-winning alcohol alternatives into diverse social settings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Healthcare Triangle Secures Major Health System Contracts and Expands AI-Powered EHR Services Nationwide
New Multi-year Wins, Platform Innovation, and AI-driven Growth Strategy Position HCTI for Sustained Growth PLEASANTON, CALIF. - May 28, 2025 (NEWMEDIAWIRE) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries today announced approximately $1.0 million of new multi-year strategic contracts wins. These include major agreements with a top-tier university medical system and the largest hospital system on the East Coast. In addition, HCTI is significantly expanding its AI and EHR integration services, reinforcing its position as a trusted innovation partner to health systems nationwide. "These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle. "We're enabling digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider." Aligned with its innovation roadmap, HCTI has also expanded its portfolio with an AI-powered a next-generation AI medical document automation platform that transforms faxes, scanned forms, and unstructured clinical text into structured, actionable data - seamlessly integrating with the electronic health record (EHR). Existing healthcare systems have realized significant benefits by automating their document management processes through The solution has also facilitated the transformation of unstructured clinical text into structured, actionable data - seamlessly integrating with electronic health records (EHR) to enhance clinical decision-making and operational efficiency "These wins and platform advancements are accelerating our shift to a recurring revenue model," added David Ayanoglou, Chief Financial Officer of HCTI. "We're delivering scalable, AI-powered solutions that improve margins, expand our footprint, and increase enterprise value. HCTI is well-positioned for long-term growth and profitability." Further strengthening its community focus, HCTI is exploring high-impact EPIC workflow integrations tailored to community health system deployments. These efforts aim to enhance clinical efficiency, streamline onboarding, and bring enterprise-grade performance to underserved and regional networks - delivering scalable solutions at lower cost. With a growing portfolio of strategic contracts, breakthrough AI platforms, and an expanding presence across enterprise and community health systems, HCTI is charting a clear path towards sustainable, technology-driven growth. The Company remains focused on delivering innovation at scale and unlocking long-term value for clients, partners, and shareholders. HCTI maintains strategic partnerships with leading public cloud providers - Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure. About Healthcare Triangle Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the "SEC") and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. Investors:1-800-617-9550ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts. The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers. During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors. GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relationsgeovax@ Contact: Media Contact:Jessica Starmanmedia@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 days ago
- Associated Press
New Book On Board Equips Corporate Boards to Navigate Governance in a Changing Business Climate
NEW YORK, NY - June 11, 2025 ( NEWMEDIAWIRE ) - Corporate governance faces increased scrutiny amid economic uncertainty and evolving expectations. Corporate board members and executives now have a unique resource: On Board: The Modern Playbook for Corporate Governance, by governance expert Jon Foster. This vital guide provides a readable historical perspective on how we got to now with a contemporary history of transactions (mergers and acquisitions, LBOs, activism, and restructurings), the growing importance of institutional investors, and the rise and now waning of environmental, social, and governance (ESG) issues that provide context for today's laws, standards, and best practices for good governance. Then, with experience, stories, and anecdotes from inside boardrooms, courtrooms, and investor meetings, Foster provides critical insights on the key issues that boards face. These include recruiting and onboarding directors, overseeing but not managing the company, board leadership, board committees, interacting effectively with the CEO, seeing that there are plans to mitigate risks and handle crises, and whether the board should target the maximization of shareholder or stakeholder value. This timely book, which addresses the dynamic landscape of governance and leadership, equips readers with the knowledge they need to navigate today's complex business environment. With experience on over 50 corporate boards, an expert witness on governance, mergers and acquisitions, restructurings and other topics in some 60 cases, and more than three decades as an investment banker, Foster offers informed views on board oversight, fiduciary responsibilities, management, shareholder engagement, and emerging governance challenges. This book provides a practical and straightforward approach to building and sustaining high-functioning boards that promote long-term success while managing risks and addressing shareholder expectations. 'As corporate governance evolves, it becomes increasingly critical for boards to clearly understand and address effectively their responsibilities and stay ahead of emerging trends,' Foster explains. 'On Board is a modern playbook for directors, offering actionable guidance rooted in lessons from the past, real-world experience, and anticipation of what may come next.' Key Themes in On Board: About Jonathan F. Foster is a deeply experienced corporate director, investment banker, and expert witness in corporate litigation. He has been on over 50 boards of directors of Fortune 500 companies, private equity firm portfolio companies, private companies, and distressed companies. He has served as a non-executive chairman, audit committee chair, and member of numerous board committees. Foster founded and is managing partner of Current Capital Partners, an advisory and merchant banking firm. Media Contact Full Name: Kathleen Schmidt Title: Founder Company Name: KMSPR Email: [email protected] Phone Number: 19734777091 Website:
